期刊
CURRENT MEDICINAL CHEMISTRY
卷 19, 期 22, 页码 3653-3663出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986712801661103
关键词
Biomarkers; body fluids; diagnosis; non-invasive; urinary; urological cancer
资金
- National Cancer Institute [RO1 CA116161]
- Florida Department of Health [10KT-01, IKF06]
The early detection of urological cancers is pivotal for successful patient treatment and management. The development of molecular assays that can diagnose disease accurately, or that can augment current methods of evaluation, would be a significant advance. Ideally, such molecular assays would be applicable to non-invasively obtained body fluids, enabling not only diagnosis of at risk patients, but also asymptomatic screening, monitoring disease recurrence and response to treatment. The advent of advanced proteomics and genomics technologies and associated bioinformatics development is bringing these goals into focus. In this article we will discuss the promise of biomarkers in urinalysis for the detection and clinical evaluation of the major urological cancers, including bladder, kidney and prostate. The development of urine-based tests to detect urological cancers would be of tremendous benefit to both patients and the healthcare system.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据